Modified interferon gamma proteins and uses thereof
Through the bioengineering of interferon gamma, the introduction of specific amino acid modifications has solved the problem of interferon gamma signaling in adult patients with epilepsy immunodeficiency, the effective activation of the immune response is achieved, and the resistance to opportunistic infection is improved .
Patent Information
- Application Number
- CN202280007040.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-22
- Publication Date
- 2024-11-15
AI Technical Summary
In adult patients with episodic immunodeficiency, autoantibodies are blocked from signaling of interferon gamma (IFN-γ)-mediated immune responses, resulting in opportunistic infections, such as non-Myanobacterium tuberculosis infection, which is difficult for the existing technology to effectively solve this problem. .
By bioengineering interferon gamma, specific amino acid modifications are introduced, such as amino acids at positions 27, 29 and 30 are replaced by alanine, aspartic acid, histidine or proline, forming discontinuous epitopes to avoid autoantibodies Combined, thereby maintaining immune response signaling capabilities.
The modified interferon γ can effectively evade the neutralization of autoantibodies, maintain interaction with receptors, stimulate immune responses, and improve resistance to opportunistic infections.
Smart Images

Figure CN118974079A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to modified or bioengineered proteins carrying at least one modification. Specifically, the disclosed modified protein is a modified interferon gamma, which, after being administered to a subject in sufficient amounts, is capable of initiating cell signaling for an immune response in the subject, while the carried modification does not substantially produce any adverse effects. Background Art
[0002] Interferon gamma (IFN-γ) is a type II interferon that exerts pleiotropic effects in the innate and adaptive immune systems [1]. It exhibits antiviral and antimycobacterial activities, antigen presentation by upregulating major histocompatibility complex (MHC) molecules, antiproliferative effects, and immunosuppressive effects [2]. IFN-γ is structurally a homodimer that consists of non-covalent self-assemblies in a head-to-tail orientation. Helical regions A and B with their connecting loops, the histidine residue at position 111 in the F helix (H111), and the flexible C-terminus are important regions for receptor binding [3]. Ligand binding induces receptor oligomerization, in which two α-receptor chains IFN-γR1 bind to one IFN-γ homodimer, followed by the recruitment of two β-receptor chains IFN-γR2 to the complex, inducing IFN-γ-stimulated gene expression [4,5].
[0003] The presence of neutralizing anti-IFN-γ autoantibodies is associated with adult-onset immunodeficiency (AOID) [6-10]. Patients lacking IFN-γ-mediated function are susceptible to opportunistic infections, especially nontuberculous mycobacterial (NTM) infections. In 2016, Lin CH et al. used 30-mer non-overlapping synthetic peptides to identify epitopes recognized by anti-IFN-γ autoantibodies. The data showed that the C-terminal region of IFN-γ (amino acids 121-131, SPAAKTGKRKR) is a continuous epitope recognized by the patient's autoantibodies
[11] . Recently, neutralizing autoantibodies that recognize discontinuous epitopes have been identified in patients with mycobacterial infections (PCT Publication No. WO 2018 / 202200A1). Ku et al. also taught a method for evaluating the efficacy of recombinant human interferon γ in regulating peripheral blood mononuclear cells in U.S. Patent No. 10273278. Conformational epitopes recognized by other neutralizing anti-IFN-γ mAbs have recently been identified using human-bovine chimeric proteins. Thus, two major epitopes located in regions A and E have been found
[13] . Furthermore, mAbs recognizing regions A and E showed varying degrees of neutralizing activity. This finding confirms that IFN-γ is composed of various conformational epitopes. However, the epitopes recognized by autoantibodies have not been fully explored. More importantly, it is possible to derive pharmaceutical agents based on the information obtained about the epitopes present on IFN-γ. Summary of the invention
[0004] The present invention aims to provide a bioengineered peptide or protein capable of forming interferon gamma, which carries modifications different from wild-type interferon gamma, but after being administered to a subject in a pharmaceutically acceptable amount, it can trigger cell signaling for an immune response in the subject.
[0005] Another object of the present invention is to provide a modified protein incorporating modifications that allow the interferon gamma formed thereof to escape interaction with at least one autoantibody, said interaction prohibiting the initiation of cellular signals for an immune response.
[0006] In addition, another object of the present invention is to provide a bioengineered interferon gamma carrying modifications located around a discontinuous epitope such that one or more specific amino acids establishing the discontinuous epitope are modified to prevent at least one autoantibody present in a subject to whom interferon gamma is administered from reacting at the discontinuous epitope, which blocks the initiation of cellular signals for an immune response.
[0007] It is a further object of the present invention to provide a method for stimulating an immune response in a subject suffering from AOID by administering the above-mentioned bioengineered peptide or modified interferon gamma protein.
[0008] According to several preferred embodiments, the present invention relates to a modified or bioengineered protein of a modified interferon gamma (IFN-γ) comprising at least one modification of the amino acids at positions 27 to 40 of the sequence as shown in SEQ ID NO. 1. More preferably, the modified IFN-γ is capable of initiating cell signaling for an immune response when administered to a subject. The formed IFN-γ is resistant to at least one autoantibody capable of neutralizing wild-type IFN-γ at a discontinuous epitope.
[0009] In further embodiments, the modification changes the discontinuous epitope of IFN-γ formed. In addition, the modification comprises substitution of at least one of the amino acids at position 27, position 29 and position 30.
[0010] In several embodiments, at least one of the amino acids at position 27, position 29, and position 30 is substituted with alanine, aspartic acid, histidine, proline, or tryptophan.
[0011] Another aspect of the present invention relates to a method for initiating or stimulating cell signaling for an immune response in a subject with adult-onset immunodeficiency (AOID), comprising the step of administering a plurality of bioengineered peptides and / or proteins. Preferably, the bioengineered peptides form an interferon gamma protein comprising at least one modification of the amino acids at positions 27 to 40 of the sequence as shown in SEQ ID NO.1.
[0012] In more embodiments of the disclosed methods, the modification comprises substitution of at least one of the amino acids at position 27, position 29, and position 30. More preferably, in several embodiments, at least one of the amino acids at position 27, position 29, and position 30 is substituted with alanine, aspartic acid, histidine, proline, or tryptophan.
[0013] Accordingly, in several embodiments of the disclosed methods, the modification alters a discontinuous epitope of the formed IFN-γ such that the formed IFN-γ is resistant to at least one autoantibody capable of neutralizing wild-type IFN-γ at the discontinuous epitope.
[0014] Further aspects of the present invention relate to a vector comprising a polynucleotide sequence that can be translated to produce a protein that forms interferon, the protein comprising at least one modification of the amino acids located at positions 27 to 40 of the sequence as shown in SEQ ID NO. 1. The modified IFN-γ is capable of initiating cell signaling for an immune response when administered to a subject. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 A query portion of the human IFN-γ structure (PDB ID: 1FG9) is depicted, wherein (A) is a single IFN-γ molecule, (B) shows a vacancy in a position on IFN-γ (highlighted), (C) shows a side view of a homodimeric arrangement of IFN-γ molecules, and (D) shows a side view of a homodimeric arrangement of IFN-γ molecules;
[0016] Figure 2 Presentation of human IFN-γ molecule 27 TLFLGILKNWKEES 40 Multiple rotated views of solvent accessible residues, where buried, exposed, and intermediate residues are classified according to %SASA of <10%, >25%, and 10%-25%, respectively;
[0017] Figure 3 Mapping of human IFN-γ molecules 27 TLFLGILKNWKEES 40Other rotated views of the intermolecular neighborhood of IFN-γ chain A and IFN-γ chain B, where the interacting and non-interacting residues on IFN-γ chain A and IFN-γ chain B are respectively based on the relationship between the two chains. and Classification of bond lengths;
[0018] Figure 4 The graph shows that IFN-γ 27 TLFLGILKNWKEES 40 's solvent accessibility, intermolecular proximity, and hydrogen bonding properties, where F29, L28, W36, L30, and N35 represent hydrogen bonds;
[0019] Figure 5 Prediction model query is shown, where (A) is the query peptide, (B) is 1FG9_mt2g, (C) is 1FG9_mt0g, (D) is 1FG9, (E) is the superposition structure of the peptide and 1FG9, and (F) is the superposition structure of 1FG9_mt2g, 1FG9_mt0g, 1FG9 and their RMSD values;
[0020] Figure 6 of graphs showing the binding activity of anti-IFN-γ mAbs to synthetic peptides, including their neutralizing activity, wherein (A) presents the results of an indirect ELISA for binding of B27 or A9 mAbs to IFN-γ synthetic peptides from residues 25-42 and residues 128-143 and (B) presents the results related to the neutralizing capacity of B27 and A9 mAbs, wherein the stimulation index is calculated by dividing the MHC class II expression after IFN-γ stimulation by the MHC class II expression before stimulation;
[0021] Figure 7 revealing the binding activity of B27 mAb to IFN-γWT and mutants, wherein (A) shows the amino acid sequences of positions 27-40 of IFN-γWT and mutants, and (B) presents Western blot analysis of B27 mAb relative to IFN-γWT, T27A, T27AF29AL30A and ΔT27-L33, wherein the presence of various IFN-γs was demonstrated using anti-6x His antibody and the band intensity of IFN-γ obtained by B27 mAb was normalized to the band intensity of various IFN-γs detected using anti-6x His mAb, and the numbers indicate the relative level of each type of modified IFN-γ;
[0022] Figure 8 The amino acid sequence of SEQ ID No. 1 of the sequence listing of wild-type IFN-γ is shown, wherein the underlined portion indicates the segment that can be subjected to the proposed modification to derive the disclosed modified IFN-γ; and
[0023] Fig. 9 The diagram shows the arrangement of multiple domains of the vector pET-21a used for translation or production of modified IFN-γ in one embodiment of the present invention. DETAILED DESCRIPTION
[0024] Hereinafter, the present invention shall be described according to the preferred embodiment and with reference to the attached description and drawings. However, it should be understood that the description with reference to the preferred embodiment and drawings of the present invention is only for the convenience of discussing the various embodiments disclosed and it is contemplated that various modifications can be designed by those skilled in the art without departing from the scope of the appended claims.
[0025] The terms "bioengineered protein", "modified protein" and "bioengineered peptide" are used interchangeably in the present invention and refer to human-made, recombinant or artificial proteins that are capable of creating modified IFN-γ molecules when placed into a substantially in vivo environment. A pharmaceutically effective dose of modified IFN-γ has the ability to initiate, trigger and / or activate an immune response in a subject receiving the modified IFN-γ.
[0026] The term "modification" as used throughout the present invention shall generally refer to one or more changes introduced biologically or chemically into a peptide sequence at the amino acid level. The changes may include addition, deletion, substitution, replacement and / or chemical variation of one or more amino acids at one or more specific positions of the modified IFN-γ compared to wild-type IFN-γ to confer preferred properties or traits to the modified IFN-γ. The modified peptide sequence, after undergoing a suitable environment, should preferably fold into the modified protein of interest.
[0027] One aspect of the present invention relates to bioengineered proteins of modified IFN or artificial IFN. One or more bioengineered proteins that produce artificial IFN can be chemically synthesized or produced by any known biological method. The modified IFN, preferably IFN-γ, is crucial. IFN-γ is a type II interferon, which is used for the innate and acquired immunity of a subject against infection. Natural or wild-type IFN-γ is mainly produced by natural killer cells and T cells of a subject (specifically, a mammal) in response to the activation of an innate immune response to an infectious agent. In several embodiments, the bioengineered protein or bioengineered peptide comprises at least one modification of the amino acids at positions 27 to 40 of the amino acid sequence as shown in SEQ ID NO.1. The amino acid arrangement of SEQ ID NO.1 corresponding to wild-type IFN-γ is as follows Figure 8 It is important to note that the resulting IFN-γ, despite the modifications introduced therein, is capable of initiating cellular signaling for an immune response when administered to a subject.
[0028] According to several preferred embodiments, the modification is intended to change the discontinuous epitope of the modified IFN-γ. The inventors of the present invention have found that the discontinuous epitope is used to bind to the IFN-γ receptor 1 (IFN-γR1) in order to induce a cell signal triggering its immune response. However, at least one autoantibody commonly present in subjects with adult-onset immunodeficiency (AOID) can also target the same discontinuous epitope. The binding of autoantibodies to this specific discontinuous epitope results in the inability of IFN-γ to interact with IFN-γR1, thereby hindering the initiation of an immune response. In view of this, the present invention proposes to produce one or more modifications at the amino acids present in the discontinuous epitope in a manner that makes the formed IFN-γ resistant to at least one autoantibody, and the autoantibody is able to neutralize wild-type IFN at the discontinuous epitope, while the interaction with IFN-γR1 remains intact or substantially unaffected. As mentioned in the above description, the disclosed bioengineered protein preferably comprises modifications of the amino acids located at positions 27 to 40 of SEQ ID NO.1. Based on the research of the present inventors, the amino acids at these positions contribute to the establishment of the mentioned discontinuous epitopes capable of binding to autoantibodies and IFN-γR1. Therefore, modification of one or more amino acids at these positions can produce a modified IFN-γ with one or more desired characteristics, which allows the modified IFN-γ to be substantially free from any interference of neutralizing autoantibodies after being administered to AOID subjects, and still has the ability to induce cellular signals for immune response. The present inventors further note that the specified range of amino acids of SEQ ID NO.1 actually spans several regions of IFN-γ. More specifically, the regions involved are the region before helix B, the region within helix B, and the corner region between helix B and helix C.
[0029] In addition, the present invention also discloses that several key amino acids within positions 27 to 40 play a greater role in the reaction of IFN-γ with autoantibodies and IFN-γR1. Specifically, it was found that the amino acids at positions 27, 29 and 30 are crucial in enabling autoantibodies and IFN-γR1 to bind to the mentioned discontinuous epitopes of IFN-γ. Therefore, the present invention intends to direct the desired modification to at least one of the amino acids at these positions, so that the resulting changes are minimal for maintaining the ability of the modified IFN-γ to induce an immune response while effectively avoiding any substantial interaction with its autoantibodies. Preferably, the modification comprises substitution of at least one of the amino acids at positions 27, 29 and 30.
[0030] Considering that such modification is intended to minimize the adverse effects of the ability to trigger an immune response to modified IFN-γ, the type of modification introduced plays a key role in determining the efficiency of the modified IFN-γ formed. According to a more preferred embodiment, at least one of the amino acids at positions 27, 29, and 30 is replaced by alanine. In more embodiments, at least one of the amino acids at positions 27, 29, and 30 can also be replaced with aspartic acid, histidine, proline, or tryptophan. The present invention finds that the original amino acid type is replaced with one of these amino acids to allow the modified protein to retain or even enhance the energy required for the discontinuous epitope to react with the receptor, while effectively reducing the autoantibodies connected thereto. In several embodiments, the modification may include replacing any one of alanine, aspartic acid, histidine, proline, or tryptophan with the amino acid at positions 27, 29, and 30.
[0031] Another aspect of the present invention relates to a method for initiating cell signaling for an immune response in a subject with adult-onset immunodeficiency (AOID). Several embodiments of the disclosed methods include administering a plurality of bioengineered or modified proteins that form a plurality of interferons, each of which comprises at least one modification of the amino acids at positions 27 to 40 of the sequence as shown in SEQ ID NO.1. In order to achieve the goal of initiating cell signaling and / or inducing an immune response, the plurality of bioengineered proteins should be administered in a pharmaceutically effective amount over a specified period of time. More embodiments of the disclosed methods may further include the step of preparing a bioengineered peptide and then administering it to an AOID subject. For example, the bioengineered protein may be premixed with one or more reagents to obtain an active form before being administered (perhaps by intravenous injection) to the subject. In some embodiments, the preparation step may include diluting the bioengineered protein to a preferred concentration, and then providing the bioengineered protein to the subject.
[0032] Likewise, the modification of the bioengineered protein used in the disclosed method comprises substitution of at least one of the amino acids at positions 27, 29, and 30 of SEQ ID NO. 1. As mentioned in the sequence shown, it was found that the amino acids at positions 27, 29, and 30 are key amino acids that enable IFN-γ to function, and the IFN-γ contributes to the cell signaling cascade of the immune response through the discontinuous epitopes in which these key amino acids are present. According to the inventors of the present invention, the T27 amino acid at position 27 of SEQ ID NO. 1 is close to the AB connecting loop and this is necessary for IFN-γ to interact with IFN-γR1. Therefore, any modification performed on T27 and / or any other amino acids located across positions 27 to 40 can weaken the interaction of the modified IFN-γ with respect to IFN-γR1 or autoantibodies. The present invention discloses that substitution of at least one of the amino acids at positions 27, 29 and 30 of the modified IFN-γ with any one of alanine, aspartic acid, histidine, proline and tryptophan only causes a reduction in reactivity with autoantibodies that target discontinuous epitopes containing these amino acids, while the interaction with IFN-γR1 appears to be equivalent or almost equivalent to wild-type IFN-γ. By administering bioengineered proteins with these modifications, the disclosed method provides a way to induce a desired immune response that is usually lacking in AOID subjects who have autoantibodies targeting wild-type IFN-γ. More specifically, the modification changes the discontinuous epitopes of the formed IFN or the formed bioengineered IFN-γ, so that the formed IFN that is resistant to at least one autoantibody is able to neutralize wild-type IFN at the discontinuous epitope.
[0033] Another aspect of the present invention may encompass a vector comprising a polynucleotide sequence capable of being translated in a compatible cell to produce a bioengineered protein of a modified interferon, the protein comprising at least one modification of the amino acids at positions 27 to 40 of the sequence as shown in SEQ ID NO.1. Preferably, the modified or formed IFN-γ is capable of initiating cell signaling for an immune response when administered to a subject. According to several preferred embodiments of the disclosed vector, the compatible cell is a BL21 (DE3) cell. The compatible cell can be configured to contain the disclosed vector by transformation or a similar process. The compatible cell transformed by the disclosed vector can be cultured in a suitable culture medium for a period of time so that the transformed cell can express the bioengineered protein.
[0034] In some embodiments, a commercial vector suitable for incorporating a modified DNA sequence is pET-21a or pQE-10. Figure 8One example of the disclosed vector is presented that is based on pET-21a. Additionally, compatible cells that can be used to host the disclosed vectors for expression of modified proteins can vary depending on the type of vector used.
[0035] In order to produce a bioengineered protein of a modified IFN-γ, the modification introduced into SEQ ID NO. 1 carried by the disclosed vector comprises substitution of at least one of the amino acids at positions 27, 29 and 30. More preferably, at least one of the amino acids at positions 27, 29 and 30 is substituted with alanine, aspartic acid, histidine, proline and / or tryptophan.
[0036] The following examples are intended to further illustrate the invention without limiting the invention to the specific embodiments described herein.
[0037] Example 1
[0038] Affinity selection or biopanning process was performed on a 12-mer phage display random peptide library (SUT12) as previously described
[15] . Briefly, three rounds of biopanning were performed by decreasing the amount of anti-IFN-γ mAb (clone B27, ImmunoTools, Friesoythe, Germany) from 10 μg, 5 μg to 2 μg in each successive round of affinity selection. After the first round of biopanning, the eluted phages were amplified overnight. After the second round, no phage amplification was performed. Individual phage clones obtained after the third round of biopanning were amplified. Their binding activity against B27 mAb was tested using phage ELISA as previously reported
[16] . Phagemids were prepared from positive phage clones in order to determine the amino acid sequence recognized by B27 mAb in the bound phage. The DNA sequence was determined using an automated DNA sequencing service using the -96gII primer (5′-CCC TCA TAG TTA GCG TAA CG-3′). The amino acid sequence was analyzed using SnapGene software.
[0039] Example 2
[0040] The query peptide sequence TDFLRMMLQEER was aligned to the full length sequence of human IFN-γ using the pairwise alignment algorithm in BioEdit. Identity and similarity were calculated using local alignments, called 'allow end slippage' in BioEdit, using the BLOSUM62 similarity matrix, a gap start penalty of 8 and a gap extension penalty of 2.
[0041] The 3D structure of human IFN-γ (PDB ID: 1FG9) was analyzed for the interaction properties of specific amino acid residues related to the query sequence, such as water accessibility, intermolecular proximity, and intermolecular hydrogen bonding. First, the homodimer structure of IFN-γ was selected and the grid-based enhanced numerical algorithm (240 grid points per atom and The solvent accessible surface area (SASA) was calculated using the probe radius. Residues with SASA < 10% were defined as buried residues, while residues with values above a threshold of 25% were called exposed residues. Second, if there were at least two atoms: one belonging to IFN-γ (chain A) and the other to IFN-γ (chain B) and the bond distance Finally, use the distance between XDA and DAY identify intermolecular hydrogen bonds within 0 to 180 degrees.
[0042] Example 3
[0043] Comparison and predicted 3D structures of the query sequence were constructed using three different structures (a peptide and two mutant IFN-γ molecules). The peptide structure consisted of 12 residues and its sequence was consistent with the query sequence TDFLRMMLQEER. As a mutant, the query structure was constructed together with the rest of human IFN-γ. Using the same template structure (PDB ID: 1FG9), the protein sequence was found to be similar to that of human full-length IFN-γ, with the exception that positions 27-40 were replaced by 27TDFLRMM--LQEER40 and 27TDFLRMMKNLQEER40, referred to as 1FG9_mt2g (127 residues) and 1FG9_0g (129 residues), respectively. K34 and N35 of 1FG9_mt0g were copied from human IFN-γ. Using the SWISS-MODEL server, the templates were searched by BLAST and HHblits using different target sequences to obtain target-template alignments. Based on the target-1FG9.A alignment, the model was built using ProMod3.
[0044] Example 4
[0045] The 3D structure of human IFN-γ was downloaded from the Protein Data Bank (PDB) (PDB ID: 1FG9)
[22] . After removing water molecules and non-protein molecules, missing atoms were added and the AMBER forcefield in the HyperChem 7.5 software package was used by brief minimization until the root mean square (RMS) gradient tolerance was 0.1000. The initial structure was optimized to remove steric clashes. The amino acid at position T27 was mutated using UCSF Chimera
[23] and then briefly minimized in a similar manner. Interaction energy (IE) analysis was calculated using IE=EAB-EA-EB, where A and B represent the residue segments that form the AB complex. In addition, the contact-based binding affinity prediction values of protein-protein complexes were analyzed using an online prediction tool (PRODIGY, http: / / milou.science.uu.nl / services / PRODIGY)
[24] .
[0046] Example 5
[0047] use Site-directed mutagenesis was performed using the Rapid Multisite-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions to generate plasmid pET21a IFN-γT27A. IFN-γT27A was amplified by PCR using plasmid pET21a IFN-γ as a template. The primers used were
[0048] 5′ATTCTTCAAAATGCCTAAGAAAAGGCTCCTCCATTATCCGCTACATCTGAATG-3′ and
[0049] 5′-cattcagatgtagcggataatggagcgcttttcttagcattttgaagaat-3′. The PCR reaction was performed at 95°C with an initial denaturation step for 2 minutes, followed by 18 cycles of denaturation at 95°C for 20 seconds, annealing at 60°C for 10 seconds and extension at 68°C for 75 seconds and finally extension at 68°C for 5 minutes. The PCR product was digested with DpnI at 37°C for 5 minutes to eliminate any methylated parental DNA template and transformed into competent E. coli strain XL1-Blue. The correct mutant clone was verified by digestion with HindIII and NheI. AmpMaster was then used. TMTaq premix (GeneAll Biotechnologies), using primers 5'-gaggaggagaagcttttagtgatggtggtgatggtgaccagaagactgggatgctcttcg-3' and 5'-gaggaggaggctagcatgcaggacccatatgtaaaagaagcagaaaaccttaagaaa-3' to perform colony PCR. The PCR reaction was performed at 95°C with an initial denaturation step for 2 minutes, followed by 30 denaturation cycles at 95°C for 30 seconds, annealing at 55°C for 30 seconds and extension at 68°C for 1 minute and finally extension at 68°C for 5 minutes. Finally, the plasmid pET21a IFN-γ mutant clone with T27A was extracted from E. coli strain XL1-Blue using the QuickGene-Mini80 kit to perform DNA sequencing.
[0050] Example 6
[0051] The cDNA sequence of IFN-γ mutant (including IFN-γT27AF29AL30A or IFN-γΔT27-L33 from pUC57 plasmid) is subcloned into pET21a IFN-γ using NheI and Bsp119I restriction enzymes.After joining, the pET21a plasmid containing the mutant IFN-γ sequence is transformed into competent Escherichia coli strain XL1-Blue. Primers 5′-gaggaggagaagcttttagtgatggtggtgatggtgaccagaagactgggatgctcttcg-3′ and 5′-gaggaggaggctagcatgcaggacccatatgtaaaagaagcagaaaaccttaagaaa-3′ are used to perform colony PCR. The clone system of correct mutation is verified by HindIII and NheI digestion. Plasmid pET21aIFN-γ mutant clones harboring IFN-γT27AF29AL30A or IFN-γΔT27-L33 were extracted from E. coli strain XL1-Blue using the QuickGene-Mini80 kit to perform DNA sequencing.
[0052] Example 7
[0053] Plasmids encoding IFN-γ wild type (WT) or mutants were transformed into BL21 (DE3) competent cells to produce recombinant IFN-γ protein (rIFN-γ). The cells were cultured overnight at 37°C in 5 ml super culture medium (SB) and then inoculated in 500 ml SB medium containing 1% glucose and 100 μg / ml ampicillin at 37°C. When the 600nm optical density (OD600nm) of the culture reached 0.8-1.0, protein expression was induced by adding 1 mM IPTG, and then cultured for 16 hours at 30°C. The induced cells expressing rIFN-γ were washed with phosphate buffered saline (PBS), dissolved by 5 minutes of sonication freeze-thaw three times, and then centrifuged at 15,000 × g for 30 minutes at 4°C. Cell pellets were collected for Western blotting.
[0054] Example 8
[0055] In order to verify whether anti-IFN-γ mAb (clone B27) is bound to IFN-γ position 27-40, indirect ELISA is performed. Microtiter plates are coated with bicarbonate buffer (pH 9.6) containing streptavidin (2 μg / ml) in each well of 50 μl and incubated overnight at 4°C in a humidified chamber. Other steps are performed at 37°C in a humidified chamber. The coated wells are washed four times with PBS containing 0.05% Tween 20. Biotin-labeled peptide 25NGTLFLGILKNWKEESDR42 (2 μg / ml) is added and cultivated for 1 hour. After washing, non-specific binding is blocked for 1 hour with blocking solution (PBS containing 2% skim milk), and 50 μl of B27 mAb (0.5 μg / ml) is added and cultivated for 1 hour. After washing four times, add 50 μ l of goat anti-mouse immunoglobulin (dilution 1:3,000) combined with HRP and cultivate for 1 hour. The reaction was developed with TMB substrate and stopped with 1N HCl. The absorbance at 450 nm was measured with an ELISA reader. In this experiment, the anti-IFN-γ mAb (clone A9, Santa Cruz Biotechnology, California, USA) that recognizes IFN-γ at position 125-143 was used as a positive control for the detection system.
[0056] Example 9
[0057] Purified IFN-γWT or BL21 (DE3) cell pellets expressing IFN-γ mutants were subjected to SDS-PAGE under reducing conditions and then transferred to nitrocellulose membranes. The membranes were blocked overnight at 4°C with PBS containing 5% skim milk. Anti-IFN-γ mAb, clone B27 (1 μg / ml) or anti-6x His antibody (0.5 μg / ml) were added and incubated with the membrane for 1 hour at room temperature with shaking. After washing, the membranes were incubated with HRP-conjugated goat anti-mouse immunoglobulin antibody (1:3000 diluted in PBS containing 2% skim milk) for 1 hour. The membranes were washed and incubated with Supersignal TM Bands were enhanced by West Pico chemiluminescent substrate (Thermo Fisher Scientific); protein bands were visualized under the ChemiDoc™ MP imaging system (Bio-Rad).
[0058] Example 10
[0059] To determine the neutralizing activity of B27 and A9 mAbs, a cell-based assay was performed. Briefly, 10 ng / ml of rIFN-γWT was incubated with 0.1, 1, or 10 μg / ml of mAb for 1 hour. The mixture was then incubated with THP-1 cells (4×10 5 After 24 hours, cells were collected to detect MHC class II surface expression by flow cytometry. Cells were washed three times with PBS and blocked for 30 minutes with PBS containing 10% AB serum. To stain MHC class II, 50 μl of anti-human HLA-DR and HLA-DP (clone HL-38) conjugated to FITC or isotype-matched controls were added to mouse IgG2a conjugated to FITC (ImmunoTools, Friesoythe, Germany) and incubated on ice for 30 minutes. After washing, cells were resuspended in 1% paraformaldehyde-PBS. BD Accuri TM Data were collected using a C6 Plus flow cytometer (BD Bioscience).
[0060] Example 11
[0061] The presence of anti-IFN-γ autoantibodies is closely associated with severe NTM and intracellular pathogen infections in patients with AOID [6-10]. Interference with IFN-γ-mediated signaling by neutralizing autoantibodies leads to immunodeficiency
[20] . The IFN-γ-IFN-γR1 interaction is the initial step in IFN-γ-mediated signaling. It has been reported that the region of IFN-γ involved in receptor binding includes a loop connecting the A and B helices (residues 18-26), helix F, and the C-terminal region [3]. Recently, autoantibodies against the C-terminal epitope were found in patients with mycobacterial infection
[11] , suggesting that autoantibodies block receptor binding, inhibit IFN-γ signaling, and lead to the development of immunodeficiency syndrome. Interestingly, in only 40% of the 63 previously reported AOID cases, the C-terminal peptide was recognized by autoantibodies
[21] . Such findings suggest that linear or conformational epitopes stimulate the production of neutralizing anti-IFN-γ autoantibodies. To better understand the pathogenesis of AOID, anti-IFN-γ autoantibodies from patients should be characterized. In the aforementioned study performed by the present inventors, the autoantibodies of AOID patients recognized the same epitope as B27 mAb
[12] . Since B27 mAb does not recognize the C-terminal epitope identified by Lin CH et al.
[11] , the epitopes of specific autoantibodies of AOID patients were further explored. In the present invention, a phage display random peptide library was selected to identify the B27 epitope. Although six phage clones were sequenced, only one peptide "TDFLRMMLQEER" was retrieved, indicating that B27 mAb has a favorable binding affinity for this specific sequence. The resulting sequences were further analyzed using BLAST and HHblits by the SWISS-MODEL server. The sequence predicted by IFN-γ (PDBID: 1FG9) is 27TLFLGILKNWKEES40, which is located just before helix B, in helix B, and in the turn between helix B and C. However, binding of the B27 mAb to this sequence was negative in ELISA, suggesting that the B27 epitope may be dependent on the discontinuous structure of IFN-γ.
[0062] Example 12
[0063] To further verify that this region is associated with IFN-γ biological activity, a computer-based analysis was performed. According to PRODIGY analysis (Table 1), T27 was identified as a key amino acid that interacts with IFN-γR1 at Y49, G50, and N79. The T27 residue is close to the AB connection loop (position 18-26) required for receptor interaction. The data suggest that autoantibodies against this region affect the IFN-γ / IFN-γR1 interaction. The results of the Western blotting method show that the binding activity of B27 mAb to T27A is significantly reduced compared with the wild type. The epitope of B27 mAb was further explored using IFN-γ mutants in which amino acids T27, F29, and L30 were substituted with alanine and seven amino acids from T27 to L33 were deleted. The binding of B27 mAb to triple mutants and T27-L33 deletion mutants was significantly reduced, and the deletion of the sequence affected the loop structure in IFN-γ. The data confirm that B27 mAb interacts favorably with the loop structure. Although T27AF29AL30A gave results similar to IFN-γ wild type, deletion of T27-L33 was found to affect the interaction energy. The findings generally support the concept that neutralizing antibodies specific for the epitope recognized by the B27 mAb are critical for inhibiting IFN-γ cellular signaling.
[0064] IFNG Receptors IE(kcal / mol) THR27 Chain B Chain D 276.80 ASN25-ALA32 TYR49GLY50ASN79 11.74 THR27 TYR49GLY50ASN79 4.29 THR27 TYR49 3.02 THR27 GLY50 1.07 THR27 ASN79 0.19 ALA27 Chain B Chain D 294.09 ASN25-ALA32 TYR49GLY50ASN79 11.18 ALA27 TYR49GLY50ASN79 3.30 ALA27 TYR49 2.27 ALA27 GLY50 0.96 ALA27 ASN79 0.08
[0065] Table 1
[0066] Based on the previously identified C-terminal epitope
[11] , the neutralization efficiency of A9 mAb and B27 mAb, which are specific for KTGKRKRSQMLFRGRRASQ, was compared. The results revealed that at the same concentration, B27 mAb neutralized IFN-γ activity much more effectively than A9 mAb. The C-terminal region is not visible in the crystal structure (PDB ID: 1FG9) due to its flexibility. Previous reports have demonstrated that the C-terminal sequence of IFN-γ is a heparin sulfate binding domain
[23] . Heparan binding to IFN-γ interferes with the IFN-γ / IFN-γR1 interaction. Although this region appears to be involved in receptor binding, truncated IFN-γ with a partial deletion of the C-terminus did not significantly change the binding affinity of IFN-γ to IFN-γR1
[23] . Therefore, we propose that the interaction of A9 mAb with the C-terminal epitope exceeds the primary interaction of IFN-γ / IFN-γR1 and partially hinders the occurrence of 2:2:2IFNγ-IFNγR1-IFNγR2 complex. In contrast, B27 mAb prevents the initial interaction of IFN-γ with IFN-γR1, a key step in cell signaling. The present invention is contemplated that the presence of neutralizing antibodies against the B27 epitope is involved in the IFN-γ signaling deficiency. Evidence can mimic the pathogenesis of AOID patients.
[0067] In addition to autoantibodies to IFN-γ, neutralizing Abs are commonly found in patients with anti-cytokine autoantibody disease (ACAD)
[24] . Several approaches exist to identify epitopes recognized by anti-cytokine autoantibodies. For anti-granulocyte macrophage colony stimulating factor (GM-CSF) in IPAP patients, neutralizing epitopes are characterized by the production of mAbs against GM-CSF by patients. These autoantibodies target at least four non-overlapping conformational epitopes on GM-CSF and are dependent on disulfide bond formation
[25] . For anti-IFN-α autoantibodies in RA patients, neutralizing epitopes were explored using phage-displayed random peptide libraries
[14] . Evidence generally suggests that neutralizing autoantibodies in ACAD can be produced by different mechanisms and display different characteristics. The results reveal that discontinuous epitopes play a major role in the pathogenesis. Herein, the inventors of the present invention successfully identified B27 mAb epitopes that are important in the pathogenesis of AOID. Phage display technology, in conjunction with structure-based analysis, provides a promising strategy for discovering discontinuous neutralizing epitopes. The lack of IFN-γ-mediated antimycobacterial activity due to anti-IFN-γ autoantibodies can lead to severe symptoms in AOID patients. Therapies that restore IFN-γ function may be suitable for patients. It has been reported that replacement of residues 121-127 of human IFN-γ (SPAAKTG) with the corresponding sequence of mice (LPESSLR) can reduce autoantibody binding and enhance the biological activity of IFN-γ in the presence of autoantibodies
[11] . This finding suggests that modification of the neutralizing epitope promotes IFN-γ to escape neutralizing autoantibodies and enhance IFN-γ-mediated function. The present invention found that a population of neutralizing anti-IFN-γ autoantibodies is close to the B27 epitope. Therefore, modifications of the characterized B27 epitope that hinder autoantibody interactions are valuable as complementary therapies for AOID patients with autoantibodies. Based on BLAST alignments, the B27 epitope is highly conserved in all vertebrates with a homology greater than 80%. Genetically engineered amino acid variants that maintain immune activity while reducing reactivity to autoantibodies would be potential candidates for the treatment of AOID. Since autoantibodies vary between individuals, identification of neutralizing epitopes of anti-IFN-γ autoantibodies will provide accurate diagnosis and treatment. The present invention provides data on the epitope recognized by B27 mAb that competes with autoantibodies in AOID patients.
[0068] The present invention may be implemented in other specific forms without departing from its structure, method or other essential features as broadly described herein and claimed below. The described embodiments should be considered in all respects as merely illustrative and not restrictive. Therefore, the scope of the present invention is specified by the appended claims rather than by the foregoing description. All changes falling within the equivalent meaning and scope of the claims should be included within their scope. Sequence Listing <110> Chiang Mai University Suranaree University of Technology <120> Modified interferon gamma protein and its use <130> CMU-P006WO <160> 1 <170> PatentIn version 3.5 <210> 1 <211> 143 <212> PRT <213> Homo sapiens <220> <221> BINDING <222> (27)..(40) <400> 1 Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys Lys Tyr Phe Asn 1 5 10 15 Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu Gly Ile 20 25 30 Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile Met Gln Ser Gln 35 40 45 Ile Val Ser Phe Tyr Phe Lys Leu Phe Lys Asn Phe Lys Asp Asp Gln 50 55 60 Ser Ile Gln Lys Ser Val Glu Thr Ile Lys Glu Asp Met Asn Val Lys 65 70 75 80 Phe Phe Asn Ser Asn Lys Lys Lys Arg Asp Asp Phe Glu Lys Leu Thr 85 90 95 Asn Tyr Ser Will Thr Asp Leu Asn Will Gln Arg Lys Ala Ile His Glu 100 105 110 Leu Ile Gln Val Met Glu Leu Ser Pro Ala Lys Thr Gly Lys 115 120 125 Arg Lys Arg Ser Gln Met Leu Phe Arg Gly Arg Arg Ala Ser Gln 130 135 140
Claims
1. A modified interferon gamma (IFN-γ) protein comprising at least one modification of the amino acids at positions 27 to 40 of the sequence as shown in SEQ ID NO. 1, wherein the modified IFN-γ is capable of initiating cell signaling for an immune response when administered to a subject.
2. The modified protein according to claim 1, wherein the modification alters the discontinuous epitope of IFN-γ formed.
3. The modified protein according to claim 2, wherein the modification comprises substitution of at least one of the amino acids at position 27, position 29 and position 30.
4. The modified protein according to claim 3, wherein at least one of the amino acids located at position 27, position 29 and position 30 is substituted with alanine, aspartic acid, histidine, proline or tryptophan.
5. The modified protein of claim 3, wherein the IFN-γ formed is resistant to at least one autoantibody capable of neutralizing wild-type IFN-γ at the discontinuous epitope.
6. A method for initiating cell signaling for an immune response in a subject with adult-onset immunodeficiency (AOID), the method comprising the step of administering a plurality of modified proteins, wherein the modified proteins are modified interferon gamma proteins comprising at least one modification of the amino acids at positions 27 to 40 of the sequence as shown in SEQ ID NO.
1.
7. The method according to claim 6, wherein the modification comprises substitution of at least one of the amino acids at position 27, position 29 and position 30.
8. The method according to claim 7, wherein at least one of the amino acids at position 27, position 29 and position 30 is substituted with alanine, aspartic acid, histidine, proline or tryptophan.
9. The method of claim 6, wherein the modification alters a discontinuous epitope of the formed IFN-γ such that the formed IFN-γ is resistant to at least one autoantibody capable of neutralizing wild-type IFN-γ at the discontinuous epitope.
10. A vector comprising a polynucleotide sequence capable of being translated to produce a modified IFN-γ protein, wherein the modified IFN-γ protein comprises at least one modification of the amino acids at positions 27 to 40 of the sequence as shown in SEQ ID NO.1, wherein the modified IFN-γ is capable of initiating cell signaling for an immune response when administered to a subject. The vector according to claim 10 , wherein the modification comprises substitution of at least one of the amino acids at position 27, position 29 and position 30. 18 . 12 . The vector according to claim 11 , wherein at least one of the amino acids at position 27, position 29, and position 30 is substituted with alanine, aspartic acid, histidine, proline, or tryptophan. The vector according to claim 10 , which is pET-21a or pQE-10.
